Loading…
State-owned Liaoning antibiotics and amino-acid API maker, one of China's earliest large-scale pharmaceutical manufacturers.
State-owned Liaoning antibiotics and amino-acid API maker, one of China's earliest large-scale pharmaceutical manufacturers.
Sells antibiotic and amino-acid ingredients in bulk to formulators and hospitals, so profit depends on global ingredient prices and plant utilisation rather than branding. State ownership gives it scale from the planned-economy era but little pricing power.
In one line: A Chinese state-owned legacy antibiotics/amino-acid maker.
Moat: none (scale). Legacy state-owned scale in commodity APIs without a differentiated product line.
Headquarters: Shenyang, China · Founded: 1946 · Employees: 5,727
Size Northeast Pharmaceutical (000597.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $948M, the 2403rd largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥4.43 on 6 Nov 2026.
Performance Over six months the shares fell 10.1%, against -12.8% for the median peer and -16.4% for the China market (cap-weighted) — 8th highest of 20 in its peer set.
Growth Revenue fell 5.8% over the last twelve months (peer median +2.4%); the operating margin is 2.7% (peer median 5.8%).
Valuation It trades at 1.0× enterprise value to sales against a peer median of 4.9× (cheapest of 17).
Price implies For today's price to make sense, revenue must grow about -7% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is -6 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 2.2 points above its cost of capital (5.0% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥6.45B | CN¥7.04B | CN¥7.47B | CN¥8.16B | CN¥8.73B |
| Revenue growth | — | -6% | -9% | -6% | — |
| Gross profit | CN¥2.59B | CN¥2.48B | CN¥2.74B | CN¥3.14B | CN¥3.23B |
| EBITDA | n/a | CN¥803M | CN¥1.06B | CN¥941M | CN¥782M |
| Net income | CN¥189M | CN¥260M | CN¥410M | CN¥358M | CN¥350M |
| Free cash flow | CN¥837M | CN¥1.01B | CN¥599M | CN¥351M | CN¥864M |
| Capital expenditure | CN¥82.2M | CN¥97.8M | CN¥159M | CN¥235M | CN¥244M |
| Total debt | CN¥4.29B | CN¥3.77B | CN¥5.54B | CN¥6.91B | CN¥5.25B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Northeast Pharmaceutical 000597.SZ | $948M | -10% | -6% | 3% | 1.0× | -6.8% |
| North China Pharmaceutical 600812.SS | $1.17B | -8% | -21% | 5% | 2.5× | 1.4% |
| Shandong Lukang Pharmaceutical 600789.SS | $1.11B | -13% | -7% | 3% | 1.6× | 3.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 000597.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -7.3% | -9.0% | 10th highest of 20 |
| 6-month return | -10.1% | -12.8% | 8th highest of 20 |
| Distance from 52-week high | -25.3% | -34.0% | 7th highest of 21 |
| Revenue growth (TTM) | -5.8% | +2.4% | 7th lowest of 18 |
| Operating margin | 2.7% | 5.8% | 8th lowest of 18 |
| EV / Sales | 1.0× | 4.9× | cheapest of 17 |
| Growth the price implies (Req g, 7 yrs) | -6.8% | 13.2% | least demanding of 11 |
| Growth delivered (Del g) | -0.7% | +6.0% | 3rd lowest of 11 |
| Hurdle (Req g minus delivered) | -6.0 pp | +6.4 pp | 3rd least demanding of 11 |
| ROIC minus cost of capital | +2.2 pp | -2.1 pp | 4th highest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Northeast Pharmaceutical 000597.SZ | China | $948M | -10% | -6% | 3% | 1.0× | -6.8% | -0.7% |
| Immatics IMTX | United States | $952M | -44% | -65% | -556% | 10.7× | n/a | n/a |
| City Therapeutics CTY | United States | $944M | n/a | +388% | -442% | n/a | n/a | n/a |
| Hunan Warrant Pharmaceutical 688799.SS | China | $942M | -20% | +5% | 9% | 4.7× | n/a | n/a |
| Nxera Pharma 4565.T | Japan | $932M | +63% | +24% | 14% | 5.1× | 16.2% | +27.3% |
| GuangYuYuan Chinese Herbal Medicine 600771.SS | China | $930M | -24% | -6% | 5% | 4.4× | 33.2% | +4.2% |
| Dezhan Healthcare 000813.SZ | China | $928M | -18% | -10% | -121% | 15.8× | n/a | n/a |
| Procter & Gamble Health PGHL.NS | India | $971M | +4% | +13% | 31% | 6.3× | 5.5% | +9.3% |
| Kissei Pharmaceutical 4547.T | Japan | $973M | -16% | +6% | 6% | 1.1× | n/a | n/a |
| Strides Pharma Science STAR.NS | India | $973M | -13% | +11% | 14% | 2.1× | 18.1% | +7.8% |
| Jiangsu Yahong Meditech 688176.SS | China | $973M | -12% | +15% | -172% | 17.8× | n/a | n/a |
| MoonLake Immunotherapeutics MLTX | United States | $981M | -32% | n/a | n/a | n/a | n/a | n/a |
| Zhejiang Garden Biopharmaceutical 300401.SZ | China | $983M | -7% | +2% | 24% | 5.5× | 10.2% | +13.4% |
| Oric Pharmaceuticals ORIC | United States | $914M | 0% | n/a | n/a | n/a | n/a | n/a |
| Bide Pharmatech 688073.SS | China | $912M | +5% | +10% | 19% | 3.6× | 16.7% | +27.7% |
| Hunan Er-Kang Pharmaceutical 300267.SZ | China | $909M | -33% | -14% | -29% | 5.2× | n/a | n/a |
| Wanbangde Pharmaceutical 002082.SZ | China | $909M | -65% | -11% | -3% | 5.9× | -1.2% | -39.5% |
| SSY 2005.HK | Hong Kong | $990M | +10% | -4% | 12% | 2.3× | 2.1% | -0.5% |
| Guizhou Bailing Group Pharmaceutical 002424.SZ | China | $907M | -12% | -25% | 2% | 2.9× | 16.2% | -0.2% |
| Savara SVRA | United States | $992M | -8% | n/a | n/a | n/a | n/a | n/a |
| Harbin Gloria Pharmaceuticals 002437.SZ | China | $999M | -15% | -16% | 13% | 3.0× | 8.8% | -6.9% |